KalVista Pharmaceuticals Inc (NAS:KALV)
$ 11.86 -0.25 (-2.06%) Market Cap: 500.35 Mil Enterprise Value: 441.07 Mil PE Ratio: 0 PB Ratio: 4.63 GF Score: 30/100

Kalvista Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 20, 2023 / 03:00PM GMT
Release Date Price: $8.16 (-0.73%)
Serge Belanger
Needham & Company, LLC - Analyst

Hi. Good morning. I'm Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to Needham's 22nd Annual Healthcare Conference. And for next session, I'm happy to welcome the KalVista Pharmaceuticals team. We have the company's CEO, Andrew Crockett; the company's CFO, Ben Palleiko; and the Chief Development Officer of the company, Chris Yea.

So I'll hand it over to Andrew. He'll give us a quick overview of KalVista, what they've been up to, I guess, what we're expecting soon in terms of data, and then we'll move on to Q&A. (Operator Instructions)

So, Andy, I'll hand it over to you.

Andrew Crockett
KalVista Pharmaceuticals, Inc. - CEO & Director

Serge, thanks for having us, pleased to be here. I'll just start with a brief introduction. So at KalVista, we're focused on discovery and development of small molecule protease inhibitors Our lead program is sebetralstat, which is a small molecule plasma kallikrein inhibitor, which is in a Phase 3 clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot